| 中文名称 | 达巴万星 |
| 英文名称 | Dalbavancin |
| CAS号 | 171500-79-1 |
| 分子式 | C88H100Cl2N10O28 |
| 分子量 | 1816.71 |
| EINECS号 | 206-141-6 |
| 熔点 | >160°C (dec.) |
| 密度 | 1.59 |
| 溶解度 | 碱性溶液(微溶)、DMSO(微溶、加热)、水(微溶) |
| 形态 | 粉末 |
| 酸度系数(pKa) | 2.73±0.70(Predicted) |
| 颜色 | 白色至米色 |
MIC90: 0.06 μg/mL ( Staphylococcus aureus ) and 0.25 μg/mL ( Bacillus anthracis )
Dalbavancin is a parenterally administered semisynthetic lipoglycopeptide developed to combat infections caused by resistant gram-positive pathogens. Dalbavancin exhibits potent in vitro bactericidal activity against gram-positive pathogens including S. aureus (MRSA), VISA, and non-VanA strains of VRE. Dalbavancin is developed for the treatment of complicated skin and skin structure infections (cSSSIs), predominantly those caused by MRSA and β-hemolytic streptococci , organisms against which it has shown greater potency than existing glycopeptide therapeutic agents.
Dalbavancin (15-240 mg/kg; intraperitoneal injection; every 36 h or 72 h; for 14 days; female BALB/c mice) treatment has a survival rate of 80% to 100% of mice with all dose regimens.
| Animal Model: | Female BALB/c mice (6-8 weeks) challenged with Ames strain of B. anthracis |
| Dosage: | 15 mg/kg, 30 mg/kg, 60 mg/kg, 120 mg/kg, 240 mg/kg |
| Administration: | Intraperitoneal injection; every 36 h or 72 h; for 14 days |
| Result: | The efficacy was 80 to 100%, as determined by the rate of survival at 42 days, when treatment was initiated 24 h postchallenge with regimens of 15 to 120 mg/kg every 36 h or 30 to 240 mg/kg every 72 h. |